1. Home
  2. Category
  3. Cancer Type

Leukemia

Article

Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment

Carissa Laudati
Caroline Clark
Andrea Knezevic
Zhigang Zhang
Margaret Barton-Burke
CJON 2018, 22(4), 407-414 DOI: 10.1188/18.CJON.407-414
Background: Strategies to reduce hypersensitivity reaction (HSR) incidence with rituximab include premedications and slow titration. Literature is lacking on the priming method used when preparing rituximab IV lines and the potential impact on HSR incidence. Objectives: The primary objective is to...
4.333335
Average: 4.3 (6 votes)
Read this Article
Perspectives

In Remission: A Patient’s Experience of Continued Care After Chronic Lymphocytic Leukemia

Andrew Schorr
Esther Schorr
CJON 2018, 22(2), 132-133 DOI: 10.1188/18.CJON.132-133
Being a patient with chronic lymphocytic leukemia and now in the midst of infusion treatment after a 17-year remission, I cannot praise oncology nurses enough. I am overwhelmed by their professionalism and warmth and I am delighted to share my perspective as a patient.
0
No votes yet
Read this Article
Online Exclusive Article

Leukostasis: Management to Prevent Crisis in Acute Leukemia

Lisa M. Blackburn
Shelly Brown
Aimee Munyon
Michelle Orovets
CJON 2017, 21(6), E267-E271 DOI: 10.1188/17.CJON.E267-E271
Background: Hyperleukocytosis, a peripheral white blood cell count greater than 100,000/mm 3 , is most commonly seen in patients with newly diagnosed or relapsed acute lymphoblastic leukemia and acute myeloid leukemia. Leukostasis is a reduction in blood flow related to hyperviscosity...
5
Average: 5 (3 votes)
Read this Article
Online Exclusive Article

Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors

Jochen Hefner
Eva-Johanna Csef
Volker Kunzmann
ONF 2017, 44(6), E232-E240 DOI: 10.1188/17.ONF.E232-E240
Purpose/Objectives: To assess adherence and coping strategies in outpatients with chronic myeloid leukemia (CML) on oral tyrosine kinase inhibitors (TKIs). Design: Prospective, descriptive. Setting: An interdisciplinary oncology outpatient clinic in Germany. Sample: 35 outpatients with CML on oral...
0
No votes yet
Read this Article
Online Exclusive Article

Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia

Van Thu Huynh
Sharon Bergeron
CJON 2017, 21(5), E248-E259 DOI: 10.1188/17.CJON.E248-E259
Background: Acute lymphoblastic leukemia (ALL) is a common cancer in children, and outcomes have greatly improved because of the refinement of multiagent chemotherapy regimens that include intensified asparaginase therapy. Asparaginase, a cornerstone of modern pediatric chemotherapy regimens for...
5
Average: 5 (3 votes)
Read this Article

Related e-Books

View More

Questions, Concerns or Requests

We're just a click away for assistance.